Charles Kurkul, MD
Hematology & Oncology · Denton, TXNPI 1134419682
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.6%), other and speaking fees — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Novartis at 28.4% of the total. 2025 is the largest year on record at $2,858, 4.0 times the $709 reported in 2019.
Across 164 payments — averaging $52.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- CTI Biopharma Corp.$2K
- Pfizer$456
- AstraZeneca$418
- E.r. Squibb & Sons, L.L.C.$289
- Karyopharm Therapeutics Inc.$282
- plus $3K from 40 others
Across 305 payments — averaging $4579.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$493K
- Eli Lilly$376K
- Genentech, Inc.$158K
- Janssen Research & Development, LLC$123K
- Amgen$77K
- Novartis$64K
- plus $106K from 9 others
What the payments were for
- Speaking & faculty fees$1,87522%
- Food & beverage$4,12148%
- Education$5006%
- Other$2,16425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,659 in reported general payments places this provider in the 65th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 38 | $672,056 |
| ImbruvicaIbrutinib | 26 | $362,139 |
| BrukinsaZanubrutinib | 21 | $293,525 |
| CalquenceAcalabrutinib Maleate | 15 | $233,179 |
| XtandiEnzalutamide | 13 | $190,479 |
| VenclextaVenetoclax | 15 | $177,109 |
| GleevecImatinib Mesylate | 13 | $134,932 |
| XareltoRivaroxaban | 108 | $86,774 |
| EliquisApixaban | 105 | $71,938 |
| Imatinib Mesylate | 11 | $49,267 |
| Fentanyl | 32 | $6,233 |
| Exemestane | 27 | $3,489 |
| Hydroxyurea | 75 | $2,468 |
| Anastrozole | 102 | $2,012 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 53 | $1,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $147 | $672,05638 claims |
| AstraZenecaCalquence | $418 | $233,17915 claims |
| Astellas Pharma US IncXtandi | $266 | $190,47913 claims |
| AbbVieVenclexta | $73 | $177,10915 claims |
| NovartisGleevec | $2,463 | $134,93213 claims |
| Johnson & JohnsonXarelto | $170 | $86,774108 claims |
| PfizerEliquis | $456 | $71,938105 claims |
| Lilly USA, LLCOlanzapine | $117 | $4612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Denton
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.